Information de reference pour ce titreAccession Number: | 00006114-201007130-00012.
|
Author: | Campbell, N.L. PharmD; Boustani, M.A. MD, MPH; Lane, K.A. MS; Gao, S. PhD; Hendrie, H. MB, ChB, DSc (Med); Khan, B.A. MD; Murrell, J.R. PhD; Unverzagt, F.W. PhD; Hake, A. MD; Smith-Gamble, V.; Hall, K. PhD
|
Institution: | From Wishard Health Services (N.L.C.); Indiana University Center for Aging Research (M.A.B., H.H.); Regenstrief Institute, Inc. (M.A.B., H.H.); Department of Medicine (M.A.B., K.A.L., S.G., B.A.K., A.H.), Indiana University School of Medicine; Departments of Psychiatry (H.H., F.W.U., V.S.-G., K.H.), Pathology and Laboratory Medicine (J.R.M.), and Neurology (A.H.), Indiana University Indianapolis; and Richard L. Roudebush Veterans Administration Medical Center (V.S.-G.), Indianapolis, IN.
|
Title: | |
Source: | Neurology. 75(2):152-159, July 13, 2010.
|
Abstract: | Background: Anticholinergic properties of certain medications often go unrecognized, and are frequently used by the elderly population. Few studies have yet defined the long-term impact of these medications on the incidence of cognitive impairment.
Methods: We report a 6-year longitudinal, observational study, evaluating 1,652 community-dwelling African American subjects over the age of 70 years who were enrolled in the Indianapolis-Ibadan Dementia Project between 2001 and 2007 and who had normal cognitive function at baseline. The exposure group included those who reported the baseline use of possible or definite anticholinergics as determined by the Anticholinergic Cognitive Burden scale. Our main outcome measure was the incidence of cognitive impairment, defined as either dementia or cognitive impairment not dementia, or poor performance on a dementia screening instrument during the follow-up period.
Results: At baseline, 53% of the population used a possible anticholinergic, and 11% used a definite anticholinergic. After adjusting for age, gender, educational level, and baseline cognitive performance, the number of definite anticholinergics was associated with an increased risk of cognitive impairment (odds ratio [OR] 1.46, 95% confidence interval [CI] 1.07-1.99; p = 0.02), whereas the number of possible anticholinergics at baseline did not increase the risk (OR 0.96, 95% CI 0.85-1.09; p = 0.55). The risk of cognitive impairment among definite anticholinergic users was increased if they were not carriers of the APOE [epsilon]4 allele (OR 1.77, 95% CI 1.03-3.05; p = 0.04).
Conclusions: Limiting the clinical use of definite anticholinergics may reduce the incidence of cognitive impairment among African Americans.
(C)2010 American Academy of Neurology
|
References: | 1. Boustani M, Ham RJ. Alzheimer disease and other dementias. In: Ham RJ, Sloane PD, Warshaw GA, Bernard MA, Flaherty E, eds. Primary Care Geriatrics: A Case-Based Approach, 5th ed, ch 16. Philadelphia: Mosby; 2007:219-236.
2. Hanlon JT, Schamder KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002;50:26-34.
3. Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008;4:311-320.
4. Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc 2007;55:1248-1253.
5. Nahin RL, Pecha M, Welmerink DB, et al, for the Ginkgo Evaluation of Memory Study Investigators. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J Am Geriatr Soc 2009;57:1197-1205.
6. Aigner TG, Mishkin M. The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 1986;45:81-87.
7. Fibiger HC, Damsma G, Day JC. Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. Adv Exp Med Biol 1991;295:399-414.
8. Miller EK, Desimone R. Scopolamine affects short-term memory but not inferior temporal neurons. NeuroReport 1993;4:81-84.
9. Haroutunian V, Greig N, Pei XF, et al. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res 1997;46:161-168.
10. Haring R, Fisher A, Marciano D, et al. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to [beta]-amyloid protein secretion. J Neurochem 1998;71:2094-2103.
11. Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein [alpha]-secretases. J Neurosci Res 2003;74:342-352.
12. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009;4:225-233.
13. Hendrie HC, Osuntokun BO, Hall KS, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African-Americans. Am J Psychiatry 1995;152:1485-1492.
14. Szwast S, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology 2007;69:1873-1880.
15. Hall KS, Ogunniyi AO, Hendrie HC, et al. A cross-cultural community based study of dementias: methods and performance of the survey instrument Indianapolis, USA, and Ibadan, Nigeria. Int J Meth Psychiatr Res 1996;6:129-142.
16. Hall KS, Hendrie HC. CSI"D" and culture fair cognitive testing. In: Copeland J, Abou-Saleh M, Blazer D, eds. Principles and Practices of Geriatric Psychiatry, 2nd ed. Sussex, England: John Wiley & Sons; 2002.
17. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry of Alzheimer's disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
18. Hendrie HC, Albert MS, Butters MA, et al. The NIH Cognitive and Emotional Health Project: report of Critical Evaluation Study Committee. Alzheimers Dement 2006;2:12-32.
19. Hendrie HC, Hall KS, Brittain HM, et al. The CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly: a replication with a US sample. J Am Geriatr Soc 1988;36:402-408.
20. American Psychiatric Association. ICD-10: The International Statistical Classification of Diseases and Related Health Problems: 1 and 2. Washington, DC: American Psychiatric Association; 1992:V.3.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. Washington, DC: American Psychiatric Association; 1987.
22. Richardson K, Fox C, Maidment I, et al, and the MRC-CFAS. Current anticholinergic medication use and cognitive impairment in the older population. Poster presented at the International Conference on Alzheimer's Disease; July 2009; Vienna, Austria.
23. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
24. Efron B. Logistic regression, survival analysis, and the Kaplan-Meier curve. JASA 1988;83:414-425.
25. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 1993;261:921-923.
26. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.
27. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
28. SAS Institute Inc. SAS/STAT User's Guide, version 9.1. Cary, NC: SAS Institute; 2009.
29. Tune LE, Egeli S. Acetylcholine and delirium. Dement Geriatr Cogn Dis 1999;10:342-344.
30. Broks P, Preston GC, Traub M, et al. Modeling dementia: effects of scopolamine on memory and attention. Neuropsychologia 1988;26:685-700.
31. Beatty WW, Butters N, Janowsky DS. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav Neural Biol 1986;45:196-211.
32. Itil T, Fink M. Anticholinergic drug-induced delirium: experimental modification, quantitative EEG, and behavioral correlations. J Nerv Ment Dis 1966;143:492-507.
33. Carriere I, Fourrier-Reglat A, Dartigues J-F, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population. Arch Intern Med 2009;169:1317-1324.
34. Murray MD, Lane KA, Gao S, et al. Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002;162:2090-2096.
35. Cacciatore F, Abete P, Ferrara N, et al. Congestive heart failure and cognitive impairment in an older population: Osservatorio Geriatrico Campano Study Group. J Am Geriatr Soc 1998;46:1343-1348.
36. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008;56:2203-2210.
|
Language: | English.
|
Document Type: | Articles.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 0028-3878
|
NLM Journal Code: | 0401060, nz0
|
DOI Number: | https://dx.doi.org/10.1212/WNL.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|